Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 2, 2000, Pages

  Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; MACROLIDE; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; CONFERENCE PAPER; CROSS RESISTANCE; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; LACTAMS; MACROLIDES; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0034454270     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314057     Document Type: Conference Paper

References (49)

1. Susceptibility of pneumococci to nine antibiotics
2. Increased resistance to penicillin of pneumococci isolated from man
3. Pneumococci relatively insensitive to penicillin in Australia and New Guinea
4. Meningitis due to relatively penicillin-resistant pneumococcus
5. Streptococcus pneumoniae resistant to penicillin and chloramphenicol
6. Emergence of multiply resistant pneumococci
7. Molecular epidemiological survey of penicillin-resistant Streptococcus pneumoniae from Asia, Europe, and North America
8. Molecular epidemiologic characterization of penicillin-resistant Streptococcus pneumoniae invasive pediatric isolates recovered in six Latin-American countries: An overview. PAHO/Rockefeller University Workshop
9. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
10. A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992-1994
11. Microbiological investigations
12. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia
13. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia
14. Severe pneumonia: When and why to hospitalize
15. Duration and route of antibiotic therapy in community-acquired pneumonia: Switch and step-down therapy
16. Community-acquired pneumonia: Epidemiology, etiology, treatment
17. In vitro selection of resistance to four β-lactams and azithromycin in Streptococcus pneuntoniae
18. The antibiotic selective process: Concentration-specific amplification of low-level resistant populations
19. In vitro selective antibiotic concentrations of β-lactams for penicillin-resistant Streptococcus pneumoniae populations
20. Antimicrobial resistance issues of the future
21. Prevalence and resistance mechanisms of common bacterial respiratory pathogens
22. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study
23. Assessing the quality of the Alexander project
24. Antibiotic-resistant pneumococci
25. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
26. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
27. Emergence of antibiotic resistance in upper and lower respiratory tract infections
28. In vitro activity of 29 antimicrobial agents against penicillin-resistant and intermediate isolates of Streptococcus pneumoniae
29. The clinical relevance of in vitro resistance to penicillin, ampicillin, amoxicillin and alternative agents for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
30. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection
31. Community-acquired pneumonia in adults: Guidelines for management, Guidelines from the Infectious Diseases Society of America
32. Community-acquired respiratory tract infections: Current strategies and future predictions
33. New pathogens in community-acquired pneumonia
34. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander Project 1992-1996
35. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme
36. Evolving resistance patterns of Streptococcus pneumoniae: A link with long-acting macrolide consumption?
37. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece
38. Molecular mechanisms of resistance to commonly used non-β-lactam drugs in Streptococcus pneumoniae
39. Other resistant gram-positive organisms (penicillin-resistant pneumococci, streptococci)
40. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
41. The macrolides: Erythromycin, clarithromycin, and azithromycin
42. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data
43. Antipneumococcal activity of gatifloxacin compared to eight other compounds by agar dilution MIC
44. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens
45. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
46. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents
47. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 results from the SENTRY antimicrobial surveillance program
48. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network